BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 33850469)

  • 1. Impact of sex differences on outcomes in patients with non-valvular atrial fibrillation undergoing left atrial appendage closure: A single-center experience.
    Zhao M; Post F; Muenzel M; Hou CR; Keil T; Yu J
    Int J Med Sci; 2021; 18(9):1990-1998. PubMed ID: 33850469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
    Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
    Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of left atrial appendage closure in non-valvular atrial fibrillation in patients over 75 years.
    Yu J; Chen H; Post F; Muenzel M; Keil T; Hou CR; Zhao M; Meng Z; Jiang L
    Heart Vessels; 2019 Nov; 34(11):1858-1865. PubMed ID: 31144099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience.
    Price MJ; Reddy VY; Valderrábano M; Halperin JL; Gibson DN; Gordon N; Huber KC; Holmes DR
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1925-1932. PubMed ID: 26627989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
    Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
    J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and outcome of patients with left atrial appendage closure in China: a single-center experience.
    Zhang J; Li C; Zhou L; Sang C; Li S; Ma C
    BMC Cardiovasc Disord; 2024 Feb; 24(1):108. PubMed ID: 38355458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of percutaneous Watchman 2.5 device versus Amplatzer Amulet for left atrial appendage closure in patients with non-valvular atrial fibrillation: A systematic review and study-level meta-analysis.
    Yasmin F; Ali E; Moeed A; Zaidi F; Umar M; Virwani V
    PLoS One; 2024; 19(2):e0295804. PubMed ID: 38354181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries.
    Holmes DR; Reddy VY; Gordon NT; Delurgio D; Doshi SK; Desai AJ; Stone JE; Kar S
    J Am Coll Cardiol; 2019 Dec; 74(23):2878-2889. PubMed ID: 31806131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center.
    Xue X; Jiang L; Duenninger E; Muenzel M; Guan S; Fazakas A; Cheng F; Illnitzky J; Keil T; Yu J
    Heart Vessels; 2018 Sep; 33(9):1068-1075. PubMed ID: 29564543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation.
    Ali M; Rigopoulos AG; Mammadov M; Torky A; Auer A; Matiakis M; Abate E; Bakogiannis C; Tzikas S; Bigalke B; Sedding D; Noutsias M
    BMC Cardiovasc Disord; 2020 Feb; 20(1):78. PubMed ID: 32050904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous left atrial appendage closure in patients with primary hemostasis disorders and atrial fibrillation.
    Dognin N; Salaun E; Champagne C; Domain G; O'Hara G; Philippon F; Paradis JM; Faroux L; Beaudoin J; O'Connor K; Bernier M; Rodés-Cabau J; Champagne J
    J Interv Card Electrophysiol; 2022 Aug; 64(2):497-509. PubMed ID: 34822043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in risk of stroke and bleeding after left atrial appendage closure with LARIAT device in patients with increased risk of stroke and bleeding: Long term results.
    Litwinowicz R; Bartus M; Kapelak B; Suwalski P; Lakkireddy D; Lee RJ; Bartus K
    Catheter Cardiovasc Interv; 2019 Nov; 94(6):837-842. PubMed ID: 30884101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of catheter-based left atrial appendage closure in patients with contraindications for long-term anticoagulation.
    Seidel A; Parwani AS; Krackhardt F; Huemer M; Attanasio P; Haverkamp W; Pieske B; Boldt LH
    Minerva Cardioangiol; 2017 Dec; 65(6):545-552. PubMed ID: 28565887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
    Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
    J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
    Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
    J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial appendage orifice diameter measured with trans-esophageal echocardiography is independently related with peri-device leakage after Watchman device implantation.
    Chen YY; Zhang YH; Chen X; Huang WP; Xu B; Su X; Chen YH
    Int J Cardiovasc Imaging; 2019 Oct; 35(10):1831-1839. PubMed ID: 31321654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of the presence of chronic kidney disease on percutaneous left trial appendage closure for atrial fibrillation: A single center experience.
    Benini Tapias J; Flores-Umanzor E; Cepas-Guillén PL; Regueiro A; Sanchís L; Broseta JJ; Cases A; Freixa X
    Nefrologia (Engl Ed); 2022; 42(3):290-300. PubMed ID: 36210618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous WATCHMAN Left Atrial Appendage Closure for Japanese Patients With Nonvalvular Atrial Fibrillation at Increased Risk of Thromboembolism - First Results From the SALUTE Trial.
    Aonuma K; Yamasaki H; Nakamura M; Ootomo T; Takayama M; Ando K; Hirao K; Morino Y; Hayashida K; Kusano K; Main ML; Saito S
    Circ J; 2018 Nov; 82(12):2946-2953. PubMed ID: 30305484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
    Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
    J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.